Sold as Tobradex, Tobradex St. Every FDA application for this active ingredient: 3 branded and 3 generic.
As of Nov 16, 2026, FDA lists 6 applications for Dexamethasone; Tobramycin (sold as Tobradex, Tobradex St), first approved Aug 18, 1988, with 0 new uses approved and 0 published complete response letters.
| Aug 18, 1988 | TobradexNDA 50592 · New combination | Sandoz | 33 | Marketed |
| Sep 28, 1988 | TobradexNDA 50616 · New dosage form | Novartis | 23 | Marketed |
| Oct 27, 1999 | Tobramycin And DexamethasoneANDA 64134 | Bausch And Lomb Inc | 9 | Marketed |
| Feb 13, 2009 | Tobradex StNDA 50818 · New dosage form | Harrow Eye | 5 | Marketed |
| Jul 15, 2021 | Tobramycin And DexamethasoneANDA 212991 | Amneal | 0 | Discontinued |
| Feb 11, 2022 | Tobramycin And DexamethasoneANDA 212715 | Padagis US | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA